Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Mod... Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member. Mehr anzeigen
Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 PR Newswire HOUSTON, Jan. 8, 2025 –...
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model PR Newswire HOUSTON, Dec. 11, 2024 Abstract published...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.01 | -0.584795321637 | 1.71 | 1.9279 | 1.7 | 26284 | 1.83344532 | CS |
| 4 | -0.02 | -1.16279069767 | 1.72 | 1.99 | 1.6 | 43155 | 1.76711438 | CS |
| 12 | -0.86 | -33.59375 | 2.56 | 3.33 | 1.5002 | 58698 | 2.31906679 | CS |
| 26 | -1.77 | -51.0086455331 | 3.47 | 3.7044 | 1.5002 | 47164 | 2.42121802 | CS |
| 52 | -5.65 | -76.8707482993 | 7.35 | 10.35 | 1.5002 | 59614 | 5.05731095 | CS |
| 156 | -21.4 | -92.6406926407 | 23.1 | 30.75 | 1.5002 | 111504 | 12.65323788 | CS |
| 260 | -12.55 | -88.0701754386 | 14.25 | 131.7 | 1.5002 | 909983 | 27.15834663 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
